Shorena Janelidze
31 – 40 of 159
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2023
-
Mark
Plasma p-tau181 and p-tau217 in discriminating PART, AD and other key neuropathologies in older adults
(
- Contribution to journal › Article
-
Mark
Cognitive effects of Lewy body pathology in clinically unimpaired individuals
(
- Contribution to journal › Article
-
Mark
Clinical effects of Lewy body pathology in cognitively impaired individuals
(
- Contribution to journal › Article
-
Mark
Plasma phosphorylated tau 217 in preclinical Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
Plasma amyloid-β42/40 and apolipoprotein E for amyloid PET pre-screening in secondary prevention trials of Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
Associations Between CSF Markers of Inflammation, White Matter Lesions, and Cognitive Decline in Individuals Without Dementia
(
- Contribution to journal › Article
-
Mark
Robustness of CSF Aβ42/40 and Aβ42/P-tau181 measured using fully automated immunoassays to detect AD-related outcomes
(
- Contribution to journal › Article
-
Mark
Optimal combinations of CSF biomarkers for predicting cognitive decline and clinical conversion in cognitively unimpaired participants and mild cognitive impairment patients : A multi-cohort study
(
- Contribution to journal › Article
-
Mark
Test-retest variability of plasma biomarkers in Alzheimer's disease and its effects on clinical prediction models
(
- Contribution to journal › Article
-
Mark
Gray matter hypoperfusion is a late pathological event in the course of Alzheimer's disease
2023) In Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism 43(4). p.565-580(
- Contribution to journal › Article